- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
New Pancreatic Cancer Drugs' Revenue Potential "Limited"
The pancreatic cancer market is set to climb from $855.8 million in 2012 to approximately $1.21 billion by 2019 (a CAGR of 5.1%), says a report from GBI Research.
The pancreatic cancer market is set to climb from $855.8 million in 2012 to approximately $1.21 billion by 2019 (a CAGR of 5.1%), says a report from GBI Research. The growth will be fueled by increasing global prevalence of the disease, coupled with the launch at least three new drugs: the recently approved Abraxane (Celgene), and the upcoming TH-302 from Threshold and Merrimack’s MM-398.
However, each of these drugs’ market penetration and subsequent impact on revenues is expected to be limited.
Katie Noon, an analyst for GBI Research, said: ““Potential targeted therapies that have previously been analyzed in clinical trials include vascular endothelial growth factor receptors and epidermal growth factor receptors, but these have had limited success. As a heterogenous disease, it is likely that a combination of targeted therapies will have to be employed to develop an effective treatment for pancreatic cancer.”
While numerous novel agents for targeted therapies are currently being analyzed in the disease’s developmental pipeline, many of these have not been investigated in a clinical setting before now, according to GBI Research.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
FDA Approves Stelara Biosimilar Selarsdi to Treat Psoriasis, Psoriatic Arthritis
April 17th 2024Alvotech’s and Teva's Selarsdi (ustekinumab-aekn), the second FDA-approved biosimilar to Stelara, is indicated to treat patients aged 6 years and above with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy and for patients aged 6 years and above with active psoriatic arthritis.
